Research programme: anti-interleukin monoclonal antibodies - MedImmune

Drug Profile

Research programme: anti-interleukin monoclonal antibodies - MedImmune

Alternative Names: Anti-IL-17 MAb - MedImmune; Anti-IL-18 MAb - MedImmune; Anti-IL-1R MAb - MedImmune; CAT-2200; MEDI-571

Latest Information Update: 03 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 18 inhibitors; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cardiovascular disorders; Gastrointestinal disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2011 Preclinical development for Rheumatoid arthritis is ongoing in United Kingdom
  • 07 Dec 2007 Preclinical trials in Rheumatoid arthritis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top